JMP keeps Human Genome at market outperform

Human Genome Sciences, Inc. was reiterated at market outperform by JMP Securities analyst Charles C. Duncan on news the company is transitioning to a late-stage drug development company. In addition to pivotal programs for Albuferon and Lymphostat, the company is gearing up its manufacturing capabilities. Human Genome's strong balance sheet supports its clinical and operating activities and is primed to realize its potential, according to Duncan. Shares of the Rockville, Md.-based biopharmaceutical company were up 28 cents, or 2.25%, at $12.73. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.